Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) will present at the TD Cowen 46th Annual Health Care Conference in Boston, March 2-4, 2026. Amit Hasija, CFO, and Lorenz Muller, Chief Commercial Officer, will speak.
A live webcast is scheduled for March 3, 2026 at 9:10 AM EST, with a replay available for approximately 90 days on the company website. Meetings can be requested through TD Cowen representatives.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MIST
On the day this news was published, MIST declined 0.58%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Executive appointment | Neutral | +1.1% | Appointment of General Counsel and Chief Compliance Officer during CARDAMYST launch. |
| Feb 03 | Equity inducement grants | Neutral | +0.5% | Inducement stock options granted to new employees under 2021 Inducement Plan. |
| Jan 26 | Product launch | Positive | -2.0% | U.S. commercial availability of CARDAMYST nasal spray for adult PSVT treatment. |
| Jan 06 | EMA filing accepted | Positive | +1.5% | EMA acceptance of MAA for etripamil (TACHYMIST) in PSVT with large EU population. |
| Dec 17 | Device partnership | Positive | -3.3% | Aptar announcement that its Bidose system delivers FDA-approved CARDAMYST nasal spray. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed alignment: positive regulatory and product milestones sometimes coincided with negative 24h price reactions, while other positive updates saw modest gains.
Over the past few months, Milestone issued several important updates. In December 2025, FDA approval for CARDAMYST nasal spray was followed in January 2026 by U.S. commercial availability and an EMA MAA acceptance for etripamil (TACHYMIST), targeting about 2 million PSVT patients in Europe. Governance and compensation updates included insider equity awards and a new General Counsel appointment effective Feb 10, 2026. Against this backdrop, the TD Cowen conference appearance fits into ongoing commercialization and investor-relations efforts.
Regulatory & Risk Context
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston.
A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com.
If you are interested in meeting with the Milestone team during the conference, please reach out to your TD Cowen representative.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.
Contact:
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
Media Relations
Rebecca Novak, rnovak@milestonepharma.com
